Reversing an earlier decision, European regulators have recommended approving Acorda Therapeutics Inc's (ACOR.O) drug Fampyra, which is designed to improve the walking ability of patients with multiple sclerosis.
Acorda shares jumped 21 percent to $32.33 in premarket trading on Friday.
The European Medicines Agency, which advises the European Commission on whether to approve new drugs, said in a statement it has recommended giving the drug conditional approval.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1310